WHO's Attempt to Navigate Commercial Influence and Conflicts of Interest in Nutrition Programs While Engaging With Non-State Actors: Reflections on WHO Guidance for Nation States C... von Rodwin, Marc A

Volltext

Clinician Conflicts of Interest at the Cleveland Clinic: The Context and Functions of Disclosure Policy and What Remains Unknown von Rodwin, Marc A

Volltext

Assessing US Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies von Rodwin, Marc A.

Volltext

Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States von Rodwin, Marc A.

Volltext

Pharmaceutical Price and Spending Controls in France: Lessons for the United States von Rodwin, Marc A.

Volltext

How the United Kingdom Controls Pharmaceutical Prices and Spending: Learning From Its Experience von Rodwin, Marc A.

Volltext

Pathways to independence: towards producing and using trustworthy evidence von Moynihan, Ray, Bero, Lisa, Hill, Sue, Johansson, Minna, Lexchin, Joel, Macdonald, Helen, Mintzes, Barbara, Pearson, Cynthia, Rodwin, Marc A, Stavdal, Anna, Stegenga, Jacob, Thombs, Brett D, Thornton, Hazel, Vandvik, Per Olav, Wieseler, Beate, Godlee, Fiona

Volltext

Attempts to redefine conflicts of interest von Rodwin, Marc A.

Volltext

German Pharmaceutical Pricing: Lessons for the United States von Rodwin, Marc A., Gerke, Sara

Volltext

Conflicts of Interest in Human Subject Research: The Insufficiency of U.S. and International Standards von Rodwin, Marc A.

Volltext

Corrigendum to “The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017” [Eur J Canc 145 (2021) 11–18] von Rodwin, Marc A., Mancini, Julien, Duran, Ségolène, Jalbert, Anne-Céline, Viens, Patrice, Maraninchi, Dominique, Gonçalves, Anthony, Marino, Patricia

Volltext

Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform von Rodwin, Marc A.

Volltext

Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use von Rodwin, Marc A.

Volltext

The No Surprises Act: A Conservative Band-Aid to Protect Business as Usual von Rodwin, Marc A, Sager, Alan

Volltext

The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017 von Rodwin, Marc A., Mancini, Julien, Duran, Ségolène, Jalbert, Anne-Céline, Viens, Patrice, Maraninchi, Dominique, Gonçalves, Anthony, Marino, Patricia

Volltext

The Case for Public Ownership of Patient Data von Rodwin, Marc A

Volltext

Clinical Trial Data as a Public Good von Rodwin, Marc A, Abramson, John D

Volltext

INTRODUCTION: Institutional Corruption and the Pharmaceutical Policy von Rodwin, Marc A.

Volltext

Five Un-Easy Pieces of Pharmaceutical Policy Reform von Rodwin, Marc A.

Volltext

Patient Data: Property, Privacy & the Public Interest von Rodwin, Marc A.

Volltext